Peptidomimetics Enhance CFTR Cell Surface Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis, particularly for patients with the ΔF508 mutation, face challenges in restoring functional CFTR protein to the cell surface, leading to limited therapeutic efficacy and frequent hospitalizations, as existing compounds like KALYDECO show low efficacy in homozygotes and heterozygotes, and existing peptide-based inhibitors exhibit suboptimal affinity and specificity for CAL PDZ.
Innovation Solution
Development of peptidomimetics with enhanced affinity for CAL PDZ, while maintaining specificity for NHERF-1 and TIP-1, to selectively inhibit the interaction between degradation-prone CFTR and CAL, facilitating increased cell surface expression of CFTR protein, which can be used alone or in combination with CFTR correctors and potentiators for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing peptide-based inhibitors are used to block CAL PDZ interaction, then CFTR degradation is reduced, but the affinity and specificity are suboptimal
Solution Approach 1:
The patent modifies the peptide structure by incorporating non-natural amino acids and chemical modifications to enhance binding affinity and specificity for CAL PDZ domain while maintaining the ability to block CFTR degradation. This transforms the molecular parameters of the inhibitor to achieve superior performance.
Solution Approach 2:
The invention creates composite peptide structures combining natural amino acid sequences with non-natural amino acid modifications, creating a hybrid molecule that exhibits both high affinity for CAL PDZ and improved pharmacological properties for therapeutic application.
2Reliability
If KALYDECO is used as monotherapy for ΔF508 homozygotes, then some chloride channel activity is restored, but therapeutic efficacy is low
Solution Approach 1:
The patent combines multiple therapeutic mechanisms by integrating CFTR stabilizing agents with compounds that enhance cell surface expression and channel function. This multi-modal approach addresses multiple defects in ΔF508-CFTR simultaneously, producing synergistic therapeutic effects that exceed monotherapy outcomes.
Solution Approach 2:
The invention targets specific molecular interactions at different locations in the CFTR pathway - stabilizing the protein structure, blocking degradation pathways at the CAL PDZ interaction site, and enhancing surface expression - thereby applying localized therapeutic actions to resolve the overall therapeutic deficiency.
3Reliability
If current CFTR treatments are applied, then some chloride conductance is restored, but frequent hospitalizations are still required
Solution Approach 1:
The patent develops combination therapies that continuously address multiple aspects of CFTR dysfunction - prevention of degradation, enhancement of surface expression, and optimization of channel function - thereby maintaining sustained therapeutic effect that reduces the need for repeated hospitalizations and interventions.
Data Source
AI summary
Compositions, kits and methods for preventing or treating cystic fibrosis are provided, which include the use of a peptidomimetic that inhibits the interaction between CAL and mutant CFTR proteins.